4Q 2017 Results and preliminary annual report

27. Feb 2018 | 2 min read

Moss, 27 February 2018
Gentian Diagnostics AS announces its results for the 4th quarter and 2017 preliminary annual results. The highlights include:
  • 11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
  • Increase in sales of fCAL turbo continues
  • Favorable development for Cystatin C in China

 

Please find the report enclosed.

The report will also be made available on www.gentian.com.

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

 
MeldingsID:  445248
 
 
 
 

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..